. . . "2" . . "94763" . "Osteonekr\u00F3za \u010Delist\u00ED jako ne\u017E\u00E1douc\u00ED \u00FA\u010Dinek l\u00E9\u010Dby urologick\u00FDch onkologick\u00FDch pacient\u016F" . "Jambura, Jan" . "Osteonekr\u00F3za \u010Delist\u00ED jako ne\u017E\u00E1douc\u00ED \u00FA\u010Dinek l\u00E9\u010Dby urologick\u00FDch onkologick\u00FDch pacient\u016F"@cs . "Osteonecrosis of the jaw as an adverse effect of therapy in urological cancer patients"@en . . "Hauer, Luk\u00E1\u0161" . . . "I" . . "Hru\u0161\u00E1k, Daniel" . . "\u010Cesk\u00E1 urologie" . . . . . . "[26F0B5EDFE53]" . "1211-8729" . "http://www.czechurol.cz/dwnld/cu_13_02_88_99.pdf" . "Osteonecrosis of the jaw as an adverse effect of therapy in urological cancer patients"@en . "4"^^ . . . "Farmakologicky navozen\u00E1 osteonekr\u00F3za \u010Delist\u00ED je vz\u00E1cn\u00E1 komplikace l\u00E9\u010Dby nejen onkologick\u00FDch pacient\u016F. Tyto l\u00E9ze jsou pops\u00E1ny jako ne\u017E\u00E1douc\u00ED \u00FA\u010Dinek ur\u010Dit\u00E9ho typu antiresorptivn\u00ED terapie anebo c\u00EDlen\u00E9 l\u00E9\u010Dby, kter\u00E1 ovliv\u0148uje kostn\u00ED metabolismus. U pacient\u016F s malign\u00EDm onemocn\u011Bn\u00EDm je riziko vzniku osteonekr\u00F3zy \u010Delist\u00ED podstatn\u011B v\u011Bt\u0161\u00ED ne\u017E u nemocn\u00FDch s metabolick\u00FDmi kostn\u00EDmi chorobami, p\u0159i\u010Dem\u017E pacienti s pokro\u010Dil\u00FDmi urologick\u00FDmi malignitami pat\u0159\u00ED mezi nejv\u00EDce rizikov\u00E9. Osteonekr\u00F3za \u010Delist\u00ED sv\u00FDmi projevy sni\u017Euje kvalitu \u017Eivota posti\u017Een\u00FDch pacient\u016F a m\u016F\u017Ee i v\u00FDznamn\u011B omezovat a\u017E znemo\u017E\u0148ovat peror\u00E1ln\u00ED p\u0159\u00EDjem stravy. Vzhledem k tomu, \u017Ee se jedn\u00E1 o pom\u011Brn\u011B ned\u00E1vno popsan\u00FD patologick\u00FD jev, nen\u00ED dosud pln\u011B objasn\u011Bna patofyziologie vzniku t\u011Bchto l\u00E9z\u00ED, neexistuje ani shoda mezi odborn\u00EDky, jak\u00FDm zp\u016Fsobem je l\u00E9\u010Dit. Terapie je obt\u00ED\u017En\u00E1, mnohdy zdlouhav\u00E1 i ne\u00FAsp\u011B\u0161n\u00E1, d\u016Fraz se proto klade na preventivn\u00ED opat\u0159en\u00ED. Auto\u0159i v p\u0159edkl\u00E1dan\u00E9m p\u0159ehledov\u00E9m sd\u011Blen\u00ED shrnuj\u00ED sou\u010Dasn\u00E9 poznatky t\u00FDkaj\u00EDc\u00ED se t\u011Bchto l\u00E9z\u00ED."@cs . "12"^^ . "Osteonekr\u00F3za \u010Delist\u00ED jako ne\u017E\u00E1douc\u00ED \u00FA\u010Dinek l\u00E9\u010Dby urologick\u00FDch onkologick\u00FDch pacient\u016F"@cs . . "RIV/00669806:_____/13:10138957!RIV14-MZ0-00669806" . . . "RIV/00669806:_____/13:10138957" . "4"^^ . "cancer patient; osteonecrosis of the jaw; adverse effects; sunitinib; bevacizumab; denosumab; bisphosphonates"@en . "Drug-related osteonecrosis of the jaw is a rare complication from treatment in patients suffering from cancer and other diseases. These lesions are described as an adverse effect of a spicific type of antiresorptive and/or biological therapy, which affects bone metabolism. The risk of osteonecrosis of the jaw is significantly higher in cancer patients than in patients with metabolic bone diseases. Patients suffering from advanced urological malignancies represent a group with a high risk for the development of these lesions. Osteonecrosis of the jaw impairs the quality of life for those affected. It may significantly restrict or completely prevent food intake. The drug-related osteonecrosis of the jaw is a condition that has only recently been described. As a result, the pathophysiology of these lesions is still poorly understood, and a consensus on the treatment has not been reached. Since the therapy of the jaw osteonecrosis is challenging, long lasting, and often has limited success, emphasis needs to be placed on preventive measures. The authors present a literature review and summarize the current knowledge about these lesions."@en . . "17" . "Farmakologicky navozen\u00E1 osteonekr\u00F3za \u010Delist\u00ED je vz\u00E1cn\u00E1 komplikace l\u00E9\u010Dby nejen onkologick\u00FDch pacient\u016F. Tyto l\u00E9ze jsou pops\u00E1ny jako ne\u017E\u00E1douc\u00ED \u00FA\u010Dinek ur\u010Dit\u00E9ho typu antiresorptivn\u00ED terapie anebo c\u00EDlen\u00E9 l\u00E9\u010Dby, kter\u00E1 ovliv\u0148uje kostn\u00ED metabolismus. U pacient\u016F s malign\u00EDm onemocn\u011Bn\u00EDm je riziko vzniku osteonekr\u00F3zy \u010Delist\u00ED podstatn\u011B v\u011Bt\u0161\u00ED ne\u017E u nemocn\u00FDch s metabolick\u00FDmi kostn\u00EDmi chorobami, p\u0159i\u010Dem\u017E pacienti s pokro\u010Dil\u00FDmi urologick\u00FDmi malignitami pat\u0159\u00ED mezi nejv\u00EDce rizikov\u00E9. Osteonekr\u00F3za \u010Delist\u00ED sv\u00FDmi projevy sni\u017Euje kvalitu \u017Eivota posti\u017Een\u00FDch pacient\u016F a m\u016F\u017Ee i v\u00FDznamn\u011B omezovat a\u017E znemo\u017E\u0148ovat peror\u00E1ln\u00ED p\u0159\u00EDjem stravy. Vzhledem k tomu, \u017Ee se jedn\u00E1 o pom\u011Brn\u011B ned\u00E1vno popsan\u00FD patologick\u00FD jev, nen\u00ED dosud pln\u011B objasn\u011Bna patofyziologie vzniku t\u011Bchto l\u00E9z\u00ED, neexistuje ani shoda mezi odborn\u00EDky, jak\u00FDm zp\u016Fsobem je l\u00E9\u010Dit. Terapie je obt\u00ED\u017En\u00E1, mnohdy zdlouhav\u00E1 i ne\u00FAsp\u011B\u0161n\u00E1, d\u016Fraz se proto klade na preventivn\u00ED opat\u0159en\u00ED. Auto\u0159i v p\u0159edkl\u00E1dan\u00E9m p\u0159ehledov\u00E9m sd\u011Blen\u00ED shrnuj\u00ED sou\u010Dasn\u00E9 poznatky t\u00FDkaj\u00EDc\u00ED se t\u011Bchto l\u00E9z\u00ED." . . "Hora, Milan" . . "CZ - \u010Cesk\u00E1 republika" . "Osteonekr\u00F3za \u010Delist\u00ED jako ne\u017E\u00E1douc\u00ED \u00FA\u010Dinek l\u00E9\u010Dby urologick\u00FDch onkologick\u00FDch pacient\u016F" .